메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

AbbVie Ranked #15 in the Inaugural Fortune 100 Best Companies to Work For Southeast Asia 2025 List

SINGAPORE, Dec. 15, 2025 -- AbbVie ASEAN has been ranked #15 in the inaugural Fortune Best Companies to Work For Southeast Asia 2025 list, in partnership with Great Place To Work®, highlighting workplaces across Singapore, Malaysia, Thailand and the Philippines. This honor builds on AbbVie's inclusion in the 2025 Best Workplaces in Asia™ list earlier this year – recognition that spans a wide geographic area assessed by Great Place to Work, covering markets across Asia and the Middle East. It underscores the strength, consistency and quality of our employee experienc
- 김갑성 기자
- 2025-12-15 09:00
Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial

Announcement Highlights: Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease. The study has enrolled a total of 65 participants in the US, Europe and Australia, each of whom was randomised to receive either steroids plus CYP-001, or steroids plus placebo. Primary evaluation period expected to complete in March 2026, with results in June 2026. CYP-001 has potential to address a major unmet need for the treatment of aGvHD, a life-threatening condition. MELBOURNE, Australia, Dec. 15, 2025 -- Cynata Therap
- 김갑성 기자
- 2025-12-15 08:25
ALL CONEC Signs MOU with MINIMAX to Accelerate Global Digital Dental Expansion

SEOUL, South Korea, Dec. 13, 2025 -- ALL CONEC has signed a memorandum of understanding (MOU) with Australian digital dental company MINIMAX to jointly promote digital implant production, marking a strategic move to expand into global markets. The collaboration will validate implant guide and prosthetic production processes on the platform and includes clinical case-based testing as well as coordination with local production partners. ALL CONEC operates a digital dental platform that integrates workflows for lab requests, design, production, settlement, and record tracking. The
- 김갑성 기자
- 2025-12-13 08:00
Keeping Loved Ones Active and Healthy During the Holidays with VARON Oxygen Concentrators

NEW YORK, Dec. 12, 2025 -- The holiday season is a time for family, celebration, and cherished moments. For individuals who rely on respiratory support, maintaining energy and wellness can be a challenge amid busy schedules, colder weather, and seasonal changes. VARON highlights practical solutions to help families ensure their loved ones stay active, healthy, and engaged throughout the festive season. Supporting Respiratory Health Through the Holidays For many seniors and individuals with chronic respiratory conditions, having access to reliable oxygen the
- 김갑성 기자
- 2025-12-12 23:16
Strategic Partnership | Sanyou Bio and KanryBio Forge Partnership to Co-Develop Key Reagents and Products for Biomarker Assay Kits

SHANGHAI, Dec. 12, 2025 -- On December 10, 2025, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio") and Wenzhou KanryBio Biotech Co., Ltd. ("KanryBio") announced a strategic collaboration agreement. The partnership will focus on the joint development of key reagents and products for biomarker assay kits. By integrating Sanyou Bio's core strengths in innovative biologics discovery with KanryBio's expertise in kit product development and manufacturing, the collaboration aims to provide global biopharmaceutical R&D clients with more efficient, precise, and rel
- 김갑성 기자
- 2025-12-12 22:00
United Imaging Intelligence at RSNA 2025: Reshaping Medicine with AI Agents

SHANGHAI, Dec. 12, 2025 -- Under the theme "Imaging the Individual", RSNA 2025 challenged the radiology community to push into new frontiers and close the gap between personalized care and global health disparities. This year, United Imaging Intelligence (UII), the AI-focused subsidiary of United Imaging Group, framed that vision with a timely question: "Agent Radiologist: Are We There Yet?" The company invited attendees to experience a new generation of AI agents capable of understanding, reasoning, and acting across the entire care pathway, bringing more precise and acce
- 김갑성 기자
- 2025-12-12 22:00
Global Attention: POGMENT Biomimetic Collagen "Stable Triple-Helix Breakthrough" --Unconventional and Astonishing

[ 메디채널 김갑성 기자 ] — LivingPhoenix Forum's 12 Conference Presentation Ignite International and Domestic Academia, Hailed by Academicians as the "iPhone Moment for Extracellular Matrix Research" CHENGDU, China, Dec. 12, 2025 -- LivingPhoenix Regenerative Technologies has drawn widespread international attention this November, presenting its world-first triple-helix biomimetic collagen across 12 high-level academic conferences. These events spanned over diverse fields including aesthetic medicine, regenerative medicine, biomaterials, and personal care. Leading academicians, reno
- 김갑성 기자
- 2025-12-12 21:46
Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18, a Potential Game-Changing saRNA Therapeutic for Duchenne Muscular Dystrophy

NANTONG, China, Dec. 12, 2025 -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in its investigator-initiated trial (IIT) of RAG-18 at Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences in Beijing. This milestone marks a transformative moment in the fight against Duchenne Muscular Dystrophy (DMD), positioning RAG-18 as a potential game-changer for the field. By utilizing a novel saRNA mechanism to upregulate UTRN expression, RAG-18 represents a revolutionary
- 김갑성 기자
- 2025-12-12 21:35
Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18 for Duchenne Muscular Dystrophy

NANTONG, China, Dec. 12, 2025 -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in its investigator-initiated trial (IIT) of RAG-18 at Peking Union Medical College Hospital (PUMCH) in Beijing. This important milestone represents a significant step forward in developing new therapies for Duchenne Muscular Dystrophy (DMD), providing a revolutionary treatment that could benefit all patients affected by this condition. The IIT is led by Professor Dai Yi, a distinguished expert in neuromu
- 김갑성 기자
- 2025-12-12 20:30
Insilico Medicine and TaiGen Achieves License Agreement to Develop and Commercialize AI-driven PHD Inhibitor for Anemia of Chronic Kidney Disease (CKD)

[ 메디채널 김갑성 기자 ] Insilico Medicine has licensed TaiGen Biotechnology exclusive rights in the Greater China area to develop, commercialize, and sub-license ISM4808, an AI-driven potential best-in-class oral PHD inhibitor with IND clearance granted in 2023. The partnership combines Insilico's generative AI discovery platform with TaiGen's regional clinical and commercial expertise to accelerate the development of ISM4808 for the treatment of Anemia of Chronic Kidney Disease (CKD). CAMBRIDGE, Mass., Dec. 12, 2025 -- Insilico Medicine ("Insilico"), a clinical-stage generativ
- 김갑성 기자
- 2025-12-12 20:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-12-19_FRI

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 19일 05시 00분